A Photodynamic Therapy Patient Survey: real-life experience from two regional services

Bernard Ho (Lead / Corresponding author), Natasha Howard, Sandra Howard, Andrea Cochrane, John Ferguson, Sally Ibbotson

Research output: Contribution to journalLetterpeer-review

Abstract

Topical photodynamic therapy (PDT) is widely used for actinic keratoses (AK), Bowen’s disease (BD) and superficial basal cell carcinoma (BCC), with a strong evidence‐base regarding efficacy and high levels of patient satisfaction. The British Association of Dermatologists published standards for PDT service delivery to ensure appropriate clinical governance, training and practices. Topical PDT involves application of a photosensitiser pro‐drug (5‐aminolaevulinic acid or methylaminolevulinate) and subsequent visible light exposure, generally using red LED light (conventional PDT; cPDT). This initiates PDT phototoxicity, usually resulting in discomfort, pain and inflammation. Daylight PDT (dPDT) is also increasingly used for AK with high levels of tolerance.
Original languageEnglish
Pages (from-to)226-229
Number of pages4
JournalPhotodermatology, Photoimmunology & Photomedicine
Volume37
Issue number3
Early online date10 Dec 2020
DOIs
Publication statusE-pub ahead of print - 10 Dec 2020

Fingerprint Dive into the research topics of 'A Photodynamic Therapy Patient Survey: real-life experience from two regional services'. Together they form a unique fingerprint.

Cite this